Fermenta Biotech Reports Strong Financial Growth: A Surge in Nutritional Markets

Fermenta Biotech Limited announced a robust financial performance for 9MFY25, showcasing a significant revenue growth driven by increased demand in human and animal nutrition segments. The company reported a strong EBITDA turnaround and highlighted significant progress in its international subsidiaries in Germany and the US.

Fermenta Biotech Limited, a leading Indian manufacturer of APIs, vitamins, and minerals, reported a notable revenue increase of 70% for the nine months ending December 2024, reaching INR 286.2 crore. This surge resulted from heightened demand in the human and animal nutrition segments and favorable pricing strategies.

The company's performance highlights include a significant rise in profit after tax to INR 43.1 crore, up from a loss of INR 16.9 crore the previous year. The German and US subsidiaries also posted impressive revenue growths of 383% and 80%, respectively, contributing to the overall strong financial results.

Managing Director Prashant Nagre cited increased market demand in North America and Europe and strategic approvals with global accounts as pivotal to the impressive performance. The company also achieved award recognitions in R&D and supply chain excellence. Fermenta remains committed to innovative solutions in green chemistry and environmental solutions.